We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4basebio Plc | LSE:4BB | London | Ordinary Share | GB00BMCLYF79 | ORD EUR1.00 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,035.00 | 1,000.00 | 1,070.00 | 1,035.00 | 1,035.00 | 1,035.00 | 96 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 335k | -5.15M | -0.4180 | -24.76 | 127.51M |
Hot Features
Premium
TIDM4BB
9 June 2022
4basebio PLC
("4basebio" or the "Company")
Annual General Meeting 2022 ("AGM")
4basebio Plc (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA and mRNA vaccines, announces that all of the resolutions proposed at its
Annual General Meeting held earlier today were duly passed.
The Company also wishes to again draw attention to the investor meeting being
held on 13 June 2022, through the Investor Meet Company platform at 10.00am.
Investors can sign up to Investor Meet Company for free and register interest
here:
https://www.investormeetcompany.com/register-investor
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396
7943
Heikki Lanckriet
Nominated Adviser +44 (0)20
7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker +44 (0)20
7220 0500
finnCap Ltd
Geoff Nash/Richard Chambers/Charlotte Sutcliffe
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery of
payloads. The immediate objectives of 4basebio are to continue the validation
of its DNA products and HermesT technology and commence revenue generation
during 2022. 4basebio also continues to advance its collaborations to
facilitate the functional validation of its DNA based products and cell and
gene delivery solutions.
END
(END) Dow Jones Newswires
June 09, 2022 06:39 ET (10:39 GMT)
1 Year 4basebio Chart |
1 Month 4basebio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
